The granted claims of the patents include the class of selective 5-HT compounds and are being developed as therapeutic agents
Suven Life Sciences has secured one product patent from Australia (2010340745), one product patent from Europe, one product patent from Hong Kong (1159626), one product patent from Israel (211747) and one product patent from Norway (335838) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents, which are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
With these new patents, Suven has a total of 21 granted patents from Australia, 15 granted patents from Europe, 16 product patents from Hong Kong, four product patents from Israel and five product patents from Norway. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.
EP News Bureau – Mumbai